[go: up one dir, main page]

ZA200508390B - Compositions and methods for the therapy of inflammatory bowel disease - Google Patents

Compositions and methods for the therapy of inflammatory bowel disease

Info

Publication number
ZA200508390B
ZA200508390B ZA200508390A ZA200508390A ZA200508390B ZA 200508390 B ZA200508390 B ZA 200508390B ZA 200508390 A ZA200508390 A ZA 200508390A ZA 200508390 A ZA200508390 A ZA 200508390A ZA 200508390 B ZA200508390 B ZA 200508390B
Authority
ZA
South Africa
Prior art keywords
compositions
therapy
methods
inflammatory bowel
bowel disease
Prior art date
Application number
ZA200508390A
Other languages
English (en)
Inventor
Lesley B Pickford
Christopher R Bebbington
Geoffrey T Yarranton
David J King
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of ZA200508390B publication Critical patent/ZA200508390B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200508390A 2003-04-23 2005-10-17 Compositions and methods for the therapy of inflammatory bowel disease ZA200508390B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46515503P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
ZA200508390B true ZA200508390B (en) 2006-06-28

Family

ID=33311000

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200508390A ZA200508390B (en) 2003-04-23 2005-10-17 Compositions and methods for the therapy of inflammatory bowel disease

Country Status (22)

Country Link
US (2) US7939076B2 (zh)
EP (1) EP1631312B1 (zh)
JP (1) JP4628357B2 (zh)
KR (1) KR100817351B1 (zh)
CN (2) CN100409897C (zh)
AT (1) ATE407698T1 (zh)
AU (1) AU2004232362C1 (zh)
BR (1) BRPI0410495A (zh)
CA (2) CA2522957C (zh)
DE (1) DE602004016499D1 (zh)
DK (1) DK1631312T3 (zh)
ES (1) ES2313039T3 (zh)
HK (1) HK1082200A1 (zh)
IL (1) IL171356A (zh)
MX (1) MXPA05011409A (zh)
NZ (1) NZ542866A (zh)
PL (1) PL1631312T3 (zh)
PT (1) PT1631312E (zh)
SG (1) SG173919A1 (zh)
SI (1) SI1631312T1 (zh)
WO (1) WO2004093908A2 (zh)
ZA (1) ZA200508390B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523142A1 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
ATE407698T1 (de) 2003-04-23 2008-09-15 Medarex Inc Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
PT1781705E (pt) 2004-06-21 2014-12-23 Medarex Llc Anticorpos contra recetor i do interferão alfa e as suas utilizações
KR101166901B1 (ko) 2010-04-16 2012-07-19 송영완 임플란트용 주입기
EP2575883B1 (en) * 2010-06-04 2019-12-04 The Brigham and Women's Hospital, Inc. Treatment of inflammatory disorders
ES2971415T3 (es) * 2010-07-26 2024-06-05 Qu Biologics Inc Composiciones antiinflamatorias inmunogénicas
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102617655B1 (ko) 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
EP2953474A4 (en) 2013-02-04 2016-12-28 Seres Therapeutics Inc COMPOSITIONS AND METHODS
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
RU2020120075A (ru) 2014-05-02 2020-07-03 Кью Байолоджикс Инк. Противомикробная иммуномодуляция
US10722468B2 (en) * 2014-08-14 2020-07-28 Brown University Compositions for stabilizing and delivering proteins
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
US11136399B2 (en) 2016-07-14 2021-10-05 Institute Of Biophysics, Chinese Academy Of Sciences Type I interferon receptor antibody and use thereof
EP3630146A1 (en) * 2017-06-02 2020-04-08 Goodgut S.L. Grape skin for use in the treatment of dysbiosis
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
RU2020117775A (ru) 2017-10-30 2021-12-01 Серес Терапеутикс, Инк. Композиции и способы для лечения устойчивости к антибиотикам
CN112056275B (zh) * 2020-09-27 2022-05-10 澎立生物医药技术（上海）有限公司 一种肠粘膜炎动物模型及其构建方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5516515A (en) 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
IL88377A (en) 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
FR2653445B1 (fr) 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0601052B1 (en) 1991-08-30 1996-10-16 Genentech, Inc. Therapeutic method for the treatment of iddm
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
US6558661B1 (en) 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
CA2171955A1 (en) * 1993-09-17 1995-03-23 Michael G. Tovey Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
WO1995013808A1 (en) 1993-11-15 1995-05-26 Cell Therapeutics, Inc. Method for selectively inhibiting il-2 signal transduction
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
DE69919327D1 (de) * 1998-01-30 2009-11-26 Allertein Therapeutics Llc Prognostische allergie- oder entzündungstest
AUPP670698A0 (en) 1998-10-23 1998-11-19 Monash University A method of regulation
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0001712D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
GB0001710D0 (en) 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP4156324B2 (ja) 2002-09-30 2008-09-24 ローム株式会社 直流−交流変換装置、及び交流電力供給方法
ATE407698T1 (de) 2003-04-23 2008-09-15 Medarex Inc Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
CA2523142A1 (en) 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
ES2641831T3 (es) * 2003-12-10 2017-11-14 E. R. Squibb & Sons, L.L.C. Anticuerpos contra interferón alfa y sus usos
PT1781705E (pt) * 2004-06-21 2014-12-23 Medarex Llc Anticorpos contra recetor i do interferão alfa e as suas utilizações

Also Published As

Publication number Publication date
SG173919A1 (en) 2011-09-29
AU2004232362B2 (en) 2007-09-06
KR100817351B1 (ko) 2008-03-26
US7939076B2 (en) 2011-05-10
NZ542866A (en) 2009-07-31
ATE407698T1 (de) 2008-09-15
CN1777444A (zh) 2006-05-24
CN100409897C (zh) 2008-08-13
IL171356A (en) 2010-11-30
KR20060015531A (ko) 2006-02-17
AU2004232362C1 (en) 2008-05-29
DE602004016499D1 (de) 2008-10-23
HK1082200A1 (en) 2006-06-02
AU2004232362A1 (en) 2004-11-04
MXPA05011409A (es) 2005-12-12
CN101318019A (zh) 2008-12-10
JP4628357B2 (ja) 2011-02-09
PT1631312E (pt) 2008-12-22
JP2006524703A (ja) 2006-11-02
WO2004093908A2 (en) 2004-11-04
SI1631312T1 (sl) 2009-02-28
US20050152901A1 (en) 2005-07-14
US20110165158A1 (en) 2011-07-07
BRPI0410495A (pt) 2006-06-13
ES2313039T3 (es) 2009-03-01
CA2522957A1 (en) 2004-11-04
EP1631312A2 (en) 2006-03-08
DK1631312T3 (da) 2009-01-19
PL1631312T3 (pl) 2009-02-27
CA2823468A1 (en) 2004-11-04
CN101318019B (zh) 2012-08-29
EP1631312B1 (en) 2008-09-10
WO2004093908A3 (en) 2005-06-02
US8828393B2 (en) 2014-09-09
CA2522957C (en) 2013-10-22

Similar Documents

Publication Publication Date Title
HK1082200A1 (en) Compositions and methods for the therapy of inflammatory bowel disease
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
TW200631594A (en) Toll like receptor 3 antagonists, methods and uses
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
DE60142614D1 (de) Inität
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
IL187079A0 (en) An oligoadenylate synthetase 1 protein, therapeutic compositions containing the same and screening methods
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
SG158098A1 (en) Toll like receptor 3 antagonists, methods and uses
MY142798A (en) Methods for preventing glyconoylation of proteins